FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. PMID 42419338 · Lancet Haematol · 2026-Jul-08 The record describes a phase 1 expansion study, not a randomized Phase II/III or Phase III/IIIb trial, and does not report a primary or key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis. PMID 42419336 · Lancet Oncol · 2026-Jul-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. PMID 42419335 · Lancet Infect Dis · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial. PMID 42415611 · Kidney Res Clin Pract · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin. PMID 42413960 · Clin Infect Dis · 2026-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study. PMID 42413781 · J Am Acad Dermatol · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. PMID 42413526 · Lancet Respir Med · 2026-Jul-07 The record describes a single-arm, Phase 1b/2 trial with a primary endpoint of ORR. It is not a randomized Phase III/IIIb or Phase II/III trial and lacks a time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Adjuvant Interferon-β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study. PMID 42410902 · J Dermatol · 2026-Jul-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
|
仅历史库存 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trial. PMID 42409316 · Pract Radiat Oncol · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 study]. PMID 42409049 · Pneumologie · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. PMID 42407012 · J Clin Oncol · 2026-Jul-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial. PMID 42406777 · Hum Reprod · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study. PMID 42403263 · Diabetes Obes Metab · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer. PMID 42427862 · Res Sq · 2026-Jul-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications. PMID 42402363 · Cancer Invest · 2026-Jul-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-Centre, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental Fat. PMID 42401423 · Aesthet Surg J · 2026-Jul-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR. PMID 42398914 · Ophthalmol Retina · 2026-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. PMID 42398520 · Lancet Oncol · 2026-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study. PMID 42398333 · Vaccine · 2026-Jul-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials. PMID 42397072 · Br J Dermatol · 2026-Jul-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges? PMID 42396965 · Int Forum Allergy Rhinol · 2026-Jul-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study. PMID 42396885 · Headache · 2026-Jul-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study. PMID 42497096 · Age Ageing · 2026-Jul-02 The study is not an oncology trial. The primary endpoint is a composite healthspan outcome (cardiovascular disease, diabetes, dementia, cancer, or death) in a general older adult population for primary prevention, not a trial of a drug for the treatment of a specific human malignant neoplasm. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis. PMID 42393486 · BioDrugs · 2026-Jul-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management. PMID 42392242 · Crit Rev Oncol Hematol · 2026-Jul-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). PMID 42391581 · J Clin Oncol · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. PMID 42389818 · Haematologica · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy. PMID 42389794 · Circ Heart Fail · 2026-Jul-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 42507446 · JAMA Netw Open · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 Studies. PMID 42400884 · Aesthet Surg J · 2026-Jul-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy in Resectable Colon Cancer: Evidence, Controversies, and an Implementation Roadmap for 2026. PMID 42390664 · Ann Surg Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials. PMID 42387164 · Dermatol Ther (Heidelb) · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines. PMID 42386770 · NPJ Vaccines · 2026-Jul-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. PMID 42386286 · J Rheumatol · 2026-Jul-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reply to Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study". PMID 42385844 · Am J Transplant · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. PMID 42385761 · Lancet Oncol · 2026-Jul-01 The trial is a Phase II study with a primary endpoint of pathological complete response, which is not a time-to-event efficacy endpoint. No Kaplan-Meier or hazard ratio data for OS, PFS, DFS, EFS, RFS, or TTP are reported. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial. PMID 42385760 · Lancet Oncol · 2026-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. PMID 42384406 · JAMA Surg · 2026-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours. PMID 42240214 · Curr Opin Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease. PMID 41504318 · Am J Gastroenterol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Precision in Practice: A Critical Overview of Recent Advances in Nasopharyngeal Cancer Management. PMID 41365475 · Int J Radiat Oncol Biol Phys · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical trials in cancer theranostics with potential near-term impact on clinical practice. PMID 39873742 · Br J Radiol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. PMID 42502892 · Int J Urol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Dietary Changes and Mortality among Participants of a Whole Food Plant-Based Pilot Study for Metastatic Breast Cancer. PMID 42473551 · Curr Dev Nutr · 2026-Jul The study is a long-term follow-up of a small randomized pilot study of a dietary intervention (whole food plant-based diet) for metastatic breast cancer. While it is oncology, human, randomized, and reports survival counts, it is excluded because: (1) It is not a Phase III/IIIb or Phase II/III trial (it is a pilot/feasibility study); (2) The intervention is dietary, not drug-containing; (3) The survival data is reported only as descriptive mortality counts at a single time point, not as a formal time-to-event analysis (e.g., Kaplan-Meier, log-rank, hazard ratio). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review. PMID 42473535 · EClinicalMedicine · 2026-Jul The record describes a systematic review of multiple myeloma trials, not an original report of a single randomized trial. Therefore, it is excluded as a non-original, review-type publication. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-frequency irreversible electroporation versus transurethral resection of the prostate for benign prostatic hyperplasia (GIANT): a single-centre, randomised, double-blind, phase 3, non-inferiority trial. PMID 42433275 · EClinicalMedicine · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Ma'aljobon (Whey) Consumption on Functional Constipation in Older Adults: A Randomized Double-Blind Controlled Trial. PMID 42428692 · Health Sci Rep · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Nipocalimab in Adults With Generalised Myasthenia Gravis: An Asian Subgroup Analysis of the Vivacity-MG3 Study. PMID 42421405 · J Clin Neurol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review. PMID 42419779 · Eur Respir Rev · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Fear of Cancer Recurrence and Coping in Young Breast Cancer Survivors: A Secondary Analysis. PMID 42400053 · Cancer Med · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |